<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2807245663
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Fomepizole Injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FOMEPIZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2767.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Immacule Lifesciences Private Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Immacule Lifesciences Private Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 461]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            QOMEL MEDICAL DRUG STORE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Navinta LLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AB34
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fomepizole is an antidote. Fomepizole is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Fomepizole</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to fomepizole or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to other medicines belonging to the same family (pyrazoles). In such case, you may also be allergic to fomepizole.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p><strong>Take special care with Fomepizole</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sudden swelling of the throat, face, lips or mouth,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness, skin rush or itching.</p><p>It is an allergic reaction. In this case, your doctor will monitor the observed signs.</p><p>If your allergic reaction becomes more important or gets worse, you should immediately stop your treatment in absence of any other obvious cause.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver problems (impaired liver function). In this situation, your doctor will ask you to perform blood test in order to monitor your liver function.</p><p>&nbsp;</p><p>Talk to your doctor before using Fomepizole</p><p>&nbsp;</p><p><strong>Other medicines and Fomepizole</strong></p><p>You should not combine medicines containing alcohol and Fomepizole. It may reduce their elimination.</p><p>&nbsp;</p><p>Fomepizole may interact with medicines that increase or decrease the effect of phenytoin, carbamazepine, cimetidine, ketoconazole and other similar medicines, although this has not been studied.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p><strong>&nbsp;</strong></p><p><strong>Use in Specific population</strong></p><p><strong>Pregnancy, breast-feeding</strong></p><p><strong>&nbsp;</strong></p><p>You should not use Fomepizole if you are pregnant or if you are breast-feeding unless absolutely necessary.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>You should not drive or use any tools or machines the first few days after treatment is discontinued.</p><p>Dizziness and vertigo may occur after treatment. If you experience any of these signs, you should not drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine will be given by your doctor. It will be given to you as a slow injection into one of your veins.</p><p>&nbsp;</p><p><u>Preparation and Method of administration</u></p><p>Fomepizole solidifies at temperatures less than 25&deg;C (77&deg;F). If the fomepizole solution has become solid in the vial, the solution should be liquefied by running the vial under warm water or by holding in the hand. Solidification does not affect the efficacy, safety, or stability of fomepizole. Using sterile technique, the appropriate dose of fomepizole should be drawn from the vial with a <strong>non-polycarbonate containing </strong>syringe and injected into <strong>at least 100 mL of sterile 0.9% sodium chloride injection or dextrose 5% injection. </strong>Mix well. The entire contents of the resulting solution should be infused over 30 minutes. Fomepizole, like all parenteral products, should be inspected visually for particulate matter prior to administration.</p><p><u>&nbsp;</u></p><p><u>Dosing of Fomepizole:</u></p><p>A loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter until ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH. All doses should be administered as a slow intravenous infusion over 30 minutes.</p><p>&nbsp;</p><p><strong>Hemodialysis:</strong></p><p>Hemodialysis should be considered in addition to fomepizole in the case of renal failure, significant or worsening metabolic acidosis, or a measured ethylene glycol or methanol concentration of greater than or equal to 50 mg/dL. Patients should be dialyzed to correct metabolic abnormalities and to lower the ethylene glycol concentrations below 50 mg/dL.</p><p>&nbsp;</p><p><strong>Dosage with Renal Dialysis:</strong></p><p>Fomepizole Injection is dialyzable and the frequency of dosing should be increased to every 4 hours during hemodialysis.</p><p>&nbsp;</p><p><strong>Fomepizole Dosing in Patients Requiring Hemodialysis</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>DOSE AT THE BEGINNING OF HEMODIALYSIS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>If &lt;6 hours since last fomepizole dose</strong></p></td><td style="vertical-align:top"><p><strong>If &ge; 6 hours since last fomepizole</strong></p><p><strong>dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Do not administer dose</p></td><td style="vertical-align:top"><p>Administer next scheduled dose</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>DOSING DURING HEMODIALYSIS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dose every 4 hours</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>DOSING AT THE TIME HEMODIALYSIS IS COMPLETED</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time between last dose and the end of</strong></p><p><strong>hemodialysis</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;1 hour</strong></p></td><td style="vertical-align:top"><p>Do not administer dose at the end of</p><p>hemodialysis</p></td></tr><tr><td style="vertical-align:top"><p><strong>1-3 hours</strong></p></td><td style="vertical-align:top"><p>Administer 1/2 of next scheduled dose</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;3 hours</strong></p></td><td style="vertical-align:top"><p>Administer next scheduled dose</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MAINTENANCE DOSING OFF HEMODIALYSIS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Give next scheduled dose 12 hours from last dose administered</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Discontinuation of fomepizole Treatment:</strong></p><p>Treatment with fomepizole may be discontinued when ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH.</p><p>&nbsp;</p><p><strong>If you forget to use Fomepizole</strong></p><p>Take the next dose as usual. Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p><p>&nbsp;</p><p>If you have been given more Fomepizole than you should, the following effects may occur:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drunkenness,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headaches,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slurred speech.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The most commonly adverse effects are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness,</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headaches.</p><p>&nbsp;</p><p>The following side effects may commonly occur:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Allergic reactions:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In administration area: injection site reaction, injection site inflammation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin: a sudden swelling of the throat, face, lips or mouth, redness, skin rush or itching.</p><p>&nbsp;</p><p>If you experience any of these signs, you should tell your doctor. He/she will monitor the observed signs.</p><p>If your allergic reaction becomes more important or gets worse, you should immediately stop your treatment in absence of any other obvious cause.</p><p>&nbsp;</p><p>Other side effects that may occur with Fomepizole:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart and circulation:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia/sinus bradycardia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collapse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Facial flush</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phlebosclerosis</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agitation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased drowsiness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toxic encephalopathy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lightheadedness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Burning/tingling in vein</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Stomach and gut:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), being sick (vomiting),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea, indigestion (dyspepsia),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haematemesis</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Alteration in the blood:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; temporary increase of liver enzymes (test done to check liver function),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased CPK (test done to check muscular function),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in some white blood cells count (eosinophils),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in red cells (anemia).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Urogenital system</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute renal failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening/increasing acute renal failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anuria</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory system</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharyngitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sinusitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary oedema</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhinorrhea/Rhinitis</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Metabolic and nutritional disorders</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypocalcaemia</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p><strong>&nbsp;</strong></p><p>Fomepizole diluted in 0.9% sodium chloride injection or dextrose 5% injection remains stable and sterile for at least 24 hours when stored refrigerated or at room temperature.</p><p>&nbsp;</p><p>Fomepizole does not contain preservatives. Therefore, maintain sterile conditions, and after dilution do not use beyond 24 hours. Solutions showing haziness, particulate matter, precipitate, discoloration, or leakage should not be used.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>The active substance is fomepizole (1.5 g per 1.5 ml of concentrate for solution for infusion).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fomepizole clear to yellow liquid at room temperature and it may be present in a solid form at room
temperature (25°C) filled in 2 mL clear glass vial. Each vial contains 1.5 mL (1 g/mL) of fomepizole.

Fomepizole Injection is available as a sterile, preservative-free solution for intravenous use, in vials containing 1.5 mL (1 g/mL) of fomepizole.

Pack size: Each carton contains one vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Navinta LLC</p><p>Ewing, NJ-08618, USA</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Immacule Lifesciences Private Limited</p><p>Village Thanthewal, Ropar Road,</p><p>Nalagarh, Solan, Himachal Pradesh</p><p>174101, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in September 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">فومِبيزول ترياق (دواءٌ مضاد للسموم) يُوصَف فومِبيزول ترياقًا لغليكول الإثيلين (كمانع التجمد) أو للتسمم بالميثانول، أو للشك في ابتلاع غليكول الإثيلين أو الميثانول، وقد يُوصَف وحده أو مع الغسل الكُلوي الدموي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدمْ فومِبيزول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كانت بك حساسية من فومِبيزول أو غيره من مكونات الدواء (المذكورة في القسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كانت بك حساسية من أدوية أخرى من نفس عائلة (البيرازولات)؛ فقد يكون بك حساسية من فومِبيزول أيضًا.</p><p>&nbsp;</p><p><strong>التحذيرات والاحتياطات</strong></p><p>&nbsp;</p><p dir="RTL"><strong>يُرجى توخَّي الحذر مع فومِبيزول</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن تعرَّضَت لما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم مفاجئ في الحلق أو الوجه أو الشفتين أو الفم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو احمرار أو هجمة جلدية أو حكة.</p><p dir="RTL">فهذا رد فعل تحسُّسي. وحينئذ سيراقب طبيبك العلامات الملحوظة.</p><p dir="RTL">إن أصبح رد فعلك التحسُّسي أشدَّ وأسوأ، فكفَّ عن العلاج فورًا ما لم تجد أي أسباب أخرى ملحوظة لهذه الحساسية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني مشكلاتٍ بالكبد (اعتلال وظائف الكبد). وهنا يطلب منك الطبيب إجراء فحص دم لمراقبة وظائف الكبد.</p><p>&nbsp;</p><p dir="RTL">استشر الطبيب قبل تناول فومِبيزول.</p><p>&nbsp;</p><p><strong>فومِبيزول مع غيره من الأدوية</strong></p><p dir="RTL">لا تجمع بين فومِبيزول وأدوية تحتوي على كحول؛ فهذا يقلل من طرح هذه الأدوية من الجسم.</p><p>&nbsp;</p><p dir="RTL">قد يتفاعل فومِبيزول مع الأدوية التي تزيد أو تنقص من تأثير فِنيتوين وكربامازيبين وسِمِتيدين وكيتوكونازول، وغيرها من الأدوية المشابهة، مع أن ذلك لم تثبته دراسةٌ بعد.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلاني إن كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام في فئات بعينها</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">لا تتناولي فومِبيزول إن كنتِ حاملًا أو مرضعًا إلا عند الضرورة القصوى.</p><p dir="RTL">إن كنتِ حاملًا أو مرضعًا، أو تظنين أنكِ حامل أو تنوين الإنجاب، فاستشيري الطبيب أو الصيدلاني قبل تناول هذا الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يُمتنع عن القيادة واستخدام الأدوات والآلات أولَ بضعة أيام بعد قطع العلاج.</p><p dir="RTL">قد يحدث دوخة أو دوار بعد العلاج؛ فيُمتنع عن القيادة واستخدام الأدوات والآلات إن ظهرت عليك أيٌّ من هذه العلامات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">هذا الدواء يُعطيه طبيبُك. ستُعطى الدواء بحقنٍ بطيء في أحد أوردتك.</p><p>&nbsp;</p><p dir="RTL"><u>تحضير الدواء وطريقة إعطائه</u></p><p dir="RTL">يتجمَّد فومِبيزول عند درجة حرارة أقل من 25 درجة مئوية (77 فهرنهايت). إن تجمَّد محلول فومِبيزول في القارورة، فينبغي تسييله بتحريك القارورة تحت ماء دافئ، أو بإمساكها بقبضة اليد. لا يؤثر هذا التجمُّد في فعالية فومِبيزول ولا سلامته ولا درجة ثباته. باتباع تدابير التعقيم، ينبغي سحب الجرعة الملائمة من فومِبيزول من القارورة بمحقنة (سرنجة) مصنوعة من مواد <strong>لا تحتوي على البولي كربونات</strong>، وحقنها في <strong>100 مل على الأقل من محلول كلوريد الصوديوم 0,9% معقَّم للحقن أو محلول دكستروز 5% معقَّم للحقن. </strong>ويُخلَط جيدًا. ينبغي إعطاء كل محتوى المحلول النهائي بالري الوريدي على مدار 30 دقيقة. ينبغي فحص فومِبيزول بالعين قبل إعطائه للتأكد من غياب مواد جزيئية، شأنه في ذلك شأن جميع المستحضرات التي تُعطَى حقنًا.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>جرعة فومِبيزول:</u></p><p dir="RTL">تُعطى جرعة تحميل بقدر 15 ملغ/كغ، يعقبها أربع جرعات قدرها 10 ملغ/كغ كل 12 ساعة، ثم 15 ملغ/كغ كل 12 ساعة، إلى أن يتعذّر استكشاف تركيزات غليكول الإثيلين أو الميثانول، أو أن تنخفض إلى أقل من 20 ملغ/دل، وتذهب أعراض المريض وتعود درجة الحموضة (الرقم الهدروجيني) لطبيعتها. تُعطى جميع الجرعات بالري الوريدي البطيء في 30 دقيقةً.</p><p>&nbsp;</p><p dir="RTL"><strong>الغسل الكُلوي الدموي:</strong></p><p dir="RTL">ينبغي التفكير جديًّا في الغسل الكُلوي الدموي بالإضافة إلى فومِبيزول في حالات الفشل الكُلَوي، أو الحُماض الأيضي (زيادة حموضة الدم) الشديد أو المتفاقم، أو أن يكون التركيز المقيس لغليكول الإثيلين أو الميثانول 50 ملغ/دل (ملّغرام/ديسيلِتر) أو أعلى. ينبغي إخضاع المرضى للغسل الكُلَوي الدموي لعلاج الاضطرابات الأيضية وتقليل تركيزات غليكول الإثيلين لأقل من 50 ملغ/دل.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة مع الغسل الكُلَوي:</strong></p><p dir="RTL">يمكن التخلص من حقن فومِبيزول بالغسل الكُلَوي، وينبغي زيادة تكرار الجرعة لكل 4 ساعات في أثناء الغسل الكُلوي الدموي.</p><p>&nbsp;</p><p dir="RTL"><strong>جرعة فومِبيزول مع المرضى الذين يلزمهم غسل كُلَوي دموي</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الجرعة في بداية الغسل الكُلوي الدموي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>إن كان أقل من 6 ساعات منذ آخر جرعة فومِبيزول</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>إن كان 6 ساعات أو أكثر منذ آخر جرعة فومِبيزول</strong></p><p dir="LTR"><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">لا تُعطى الجرعة</p></td><td style="vertical-align:top"><p dir="RTL">تُعطى الجرعة التالية وفق جدولها</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الجرعة في أثناء الغسل الكُلوي الدموي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">جرعة كل 4 ساعات</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>الجرعة عند إتمام الغسل الكُلوي الدموي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الزمن بين آخر جرعة وانتهاء</strong></p><p dir="RTL"><strong>الغسل الكُلوي الدموي</strong></p></td><td style="vertical-align:top"><p dir="LTR"><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>أقل من ساعة</strong></p></td><td style="vertical-align:top"><p dir="RTL">لا تُعطى الجرعة في نهاية</p><p dir="RTL">الغسل الكُلوي الدموي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>من ساعة إلى 3 ساعات</strong></p></td><td style="vertical-align:top"><p dir="RTL">تُعطى نصف الجرعة التالية وفق جدولها</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>أكثر من 3 ساعات</strong></p></td><td style="vertical-align:top"><p dir="RTL">تُعطى الجرعة التالية وفق جدولها</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>جرعة المداومة من دون الغسل الكلوي الدموي</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تُعطى الجرعة التالية وفق الجدول بعد 12 ساعة من آخر جرعة أُعطيَت</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إيقاف العلاج بفومِبيزول:</strong></p><p dir="RTL">قد يُقطع العلاج بفومِبيزول عندما لا تُستَكشَف تركيزات غليكول الإثيلين أو الميثانول، أو عند انخفاضها إلى أقل من 20 ملغ/دل، واختفاء أعراض المريض وعودة درجة الحموضة (الرقم الهيدروجيني) لطبيعتها.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول فومِبيزول</strong></p><p dir="RTL">تُعطى الجرعة التالية كالمعتاد. ولا تضاعف الجرعة لتعويض الجرعة المنسيَّة.</p><p dir="RTL">إن كانت لك أسئلة أخرى عن استعمال هذا الدواء، فاسأل طبيبك.</p><p>&nbsp;</p><p dir="RTL">إن أُعطيت جرعة فومِبيزول أكثر مما ينبغي؛ فقد تحدث الآثار الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالسُكْر،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوُّش الرؤية،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلعثُم في الكلام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء آثارًا جانبية كحال جميع الأدوية، ولكنها لا تصيب الجميع. أكثر الآثار الجانبية شيوعًا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p>&nbsp;</p><p>قد يشيع حدوث الآثار الجانبية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ردود فعل تحسُّسية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في موضع إعطاء الدواء: رد فعل في مكان الحقن، والتهابه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلد: تورُّم مفاجئ في الحلق أو الوجه أو الشفتين أو الفم، أو احمرار أو هجمة جلدية أو حكة.</p><p>&nbsp;</p><p dir="RTL">ينبغي إخبار الطبيب إن ظهرت عليك أيٌّ من هذه العلامات، وحينئذ سيراقب طبيبك العلامات الملحوظة.</p><p dir="RTL">إن أصبح رد فعلك التحسُّسي أشدَّ وأسوأ، فكفَّ عن العلاج فورًا ما لم تجد أي أسباب أخرى ملحوظة لهذه الحساسية.</p><p>&nbsp;</p><p>الآثار الجانبية الأخرى التي قد تحدث مع فومِبيزول:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القلب ودوران الدم:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء القلب أو بطء القلب الجيبيّ</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط الدورة الدموية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلّب وريديّ</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجهاز العصبي:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هياج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة النُعاس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اعتلال دماغيّ سُمّي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بخفة الرأس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بحرق أو وخز بالأوردة</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المعدة والأمعاء:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالغثيان، تقيؤ،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، عسر هضم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فواق (زغطة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بالمعدة والأمعاء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قَيءُ الدَّم</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التغيرات في الدم:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مؤقت في إنزيمات الكبد (يُجرى فحص لوظائف الكبد)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع إنزيم كِرْياتين فُسْفُوكِيناز CPK (يُجرى فحص الوظائف العضلية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في تعداد بعض خلايا الدم البيضاء (الأَيوزينيّات)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خلايا الدم الحمراء (فقر الدم).</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجهاز البوليّ التّناسليّ</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كلوي حاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور حالة الفشل الكلوي الحاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع البول</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجهاز التنفسي</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الأنفية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة رئوية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف أو التهاب الأنف</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضطرابات الأيض والتغذية</strong></p><p>نقص الكالسيوم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ هذا الدواء بعيدًا عن مرأى الأطفال ومتناولهم.</p><p>&nbsp;</p><p dir="RTL">يُحفظ تحت 30 درجة مئوية.</p><p><strong>&nbsp;</strong></p><p dir="RTL">فومِبيزول المخفَّف في محلول كلوريد الصوديوم 0,9% للحقن أو محلول دكستروز 5% للحقن، يظل ثابتًا ومعقَّمًا على الأقل 24 ساعة عند حفظه في الثلاجة (البرّاد) أو في درجة حرارة الغرفة.</p><p>&nbsp;</p><p dir="RTL">لا يحتوي فومِبيزول على مواد حافظة. ولذلك يحافَظ على حالة التعقيم، ولا يُستعمل بعد 24 ساعة من تخفيفه. لا تُستعمل المحاليل التي يظهر عليها ضبابية أو مواد جزيئية أو ترسبات أو تغير اللون أو تسرُّب.</p><p>&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المبيَّن على الملصق، ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">لا يصح التخلص من الأدوية في مياه الصرف الصحي أو مع مخلفات المنزل. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستعملها؛ فهذه التدابير تساعد على الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">مكونات فومِبيزول للحقن</p><p>&nbsp;</p><p dir="RTL">المادة الفعالة فومِبيزول (1,5 غ لكل 1,5 مل لتحضير محلول مركز للري الوريدي).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فومِبيزول سائل شفاف مصفرّ في درجة حرارة الغرفة، وقد يتخذ شكلًا متجمدًا في درجة حرارة الغرفة (25 درجة مئوية) معبَّأ في قارورة زجاجية سعتها 2 مل.</p><p dir="RTL">&nbsp;تحتوي كل قارورة على 1,5 مل (1 غ/مل) من فومِبيزول.</p><p>&nbsp;</p><p dir="RTL">يأتي فومِبيزول للحقن في صورة محلول معقَّم خالٍ من المواد الحافظة، في قوارير تحتوي على 1,5 مل (1 غ/مل) من فومِبيزول.</p><p>&nbsp;</p><p>حجم العبوة: كل علبة بها قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">نافينتا إل إل سي</p><p dir="RTL">إيوينغ، نيوجيرسي 08618، الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة إماكيول لايف ساينس المحدودة</p><p dir="RTL">قرية ثانثوال، طريق روبار،</p><p dir="RTL">نالاجاره، سولان، هيماشال براديش</p><p>174101، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجِعَت هذه النشرة آخر مرة في سبتمبر 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fomepizole 1.5 g/1.5 mL (1 g/ 1 mL) concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 1 g of Fomepizole.
One 1.5 ml vial contains 1.5 g of Fomepizole.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.

It is a clear to yellow liquid at room temperature. Its melting point is 25°C (77°F) and it may present as solid form at room temperature.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fomepizole is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment Guidelines: </strong>If ethylene glycol or methanol poisoning is left untreated, the natural progression of the poisoning leads to accumulation of toxic metabolites, including glycolic and oxalic acids (ethylene glycol intoxication) and formic acid (methanol intoxication). These metabolites can induce metabolic acidosis, nausea/vomiting, seizures, stupor, coma, calcium oxaluria, acute tubular necrosis, blindness, and death.</p><p>The diagnosis of these poisonings may be difficult because ethylene glycol and methanol concentrations diminish in the blood as they are metabolized to their respective metabolites. Hence, both ethylene glycol and methanol concentrations and acid base balance, as determined by serum electrolyte (anion gap) and/or arterial blood gas analysis, should be frequently monitored and used to guide treatment.</p><p>Treatment consists of blocking the formation of toxic metabolites using inhibitors of alcohol dehydrogenase, such as fomepizole, and correction of metabolic abnormalities.</p><p>In patients with high ethylene glycol or methanol concentrations (&ge; 50 mg/dL), significant metabolic acidosis, or renal failure, hemodialysis should be considered to remove ethylene glycol or methanol and the respective toxic metabolites of these alcohols.</p><p><strong>&nbsp;</strong></p><p><strong>Treatment with fomepizole :</strong></p><p>Begin fomepizole treatment immediately upon suspicion of ethylene glycol or methanol ingestion based on patient history and/or anion gap metabolic acidosis, increased osmolar gap, visual disturbances, or oxalate crystals in the urine, <strong>OR </strong>a documented serum ethylene glycol or methanol concentration greater than 20 mg/dL.</p><p><strong>&nbsp;</strong></p><p><strong>Hemodialysis :</strong></p><p>Hemodialysis should be considered in addition to fomepizole in the case of renal failure, significant or worsening metabolic acidosis, or a measured ethylene glycol or methanol concentration of greater than or equal to 50 mg/dL. Patients should be dialyzed to correct metabolic abnormalities and to lower the ethylene glycol concentrations below 50 mg/dL.</p><p>&nbsp;</p><p><strong>Dosing of fomepizole :</strong></p><p>A loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter until ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH. All doses should be administered as a slow intravenous infusion over 30 minutes. (see Administration).</p><p>&nbsp;</p><p><strong>Dosage with Renal Dialysis :</strong></p><p>Fomepizole Injection is dialyzable and the frequency of dosing should be increased to every 4 hours during hemodialysis.</p><p><strong>Fomepizole Dosing in Patients Requiring Hemodialysis</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>DOSE AT THE BEGINNING OF HEMODIALYSIS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>If &lt;6 hours since last fomepizole dose</strong></p></td><td style="vertical-align:top"><p><strong>If &ge; 6 hours since last fomepizole</strong></p><p><strong>dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Do not administer dose</p></td><td style="vertical-align:top"><p>Administer next scheduled dose</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>DOSING DURING HEMODIALYSIS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dose every 4 hours</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>DOSING AT THE TIME HEMODIALYSIS IS COMPLETED</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Time between last dose and the end of</strong></p><p><strong>hemodialysis</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;1 hour</strong></p></td><td style="vertical-align:top"><p>Do not administer dose at the end of</p><p>hemodialysis</p></td></tr><tr><td style="vertical-align:top"><p><strong>1-3 hours</strong></p></td><td style="vertical-align:top"><p>Administer 1/2 of next scheduled dose</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt;3 hours</strong></p></td><td style="vertical-align:top"><p>Administer next scheduled dose</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MAINTENANCE DOSING OFF HEMODIALYSIS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Give next scheduled dose 12 hours from last dose administered</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Elderly patients :</strong></p><p>Clinical experience in elderly patients is limited. The regimen has to be adjusted to the renal function (see above).</p><p><strong>&nbsp;</strong></p><p><strong>Children :</strong></p><p>There is no available data regarding the pharmacokinetics of fomepizole in children. Clinical experienceis limited and based on</p><p>similar weight-adjusted doses.</p><p>&nbsp;</p><p><strong>Patients with impaired liver function :</strong></p><p>No clinical data are available.</p><p><strong>&nbsp;</strong></p><p><strong>Administration :</strong></p><p>Fomepizole solidifies at temperatures less than 25&deg;C (77&deg;F). If the fomepizole solution has become solid in the vial, the solution should be liquefied by running the vial under warm water or by holding in the hand. Solidification does not affect the efficacy, safety, or stability of fomepizole. Using sterile technique, the appropriate dose of fomepizole should be drawn from the vial with a <strong>non-polycarbonate containing </strong>syringe and injected into <strong>at least 100 mL of sterile 0.9% sodium chloride injection or</strong> <strong>dextrose 5% injection. </strong>Mix well. The entire contents of the resulting solution should be infused over 30 minutes. Fomepizole, like all parenteral products, should be inspected visually for particulate matter prior to administration.</p><p><strong>&nbsp;</strong></p><p><strong>Discontinuation of fomepizole Treatment :</strong></p><p>Treatment with fomepizole may be discontinued when ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fomepizole should not be administered to patients with a documented serious hypersensitivity reaction to fomepizole or other pyrazoles.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General :</strong></p><p><strong>Fomepizole should not be given undiluted or by bolus injection. </strong>Venous irritation and phlebosclerosis were noted in two of six normal volunteers given bolus injections (over 5 minutes) of fomepizole at a concentration of 25 mg/mL.</p><p>&nbsp;</p><p>Patients intoxicated with ethylene glycol must be managed for metabolic acidosis and acute</p><p>renal failure in addition to specific antidote treatment with Fomepizole Injection. Intravenous fluid</p><p>therapy and sodium bicarbonate administration are necessary supportive therapies. In</p><p>addition, potassium and calcium supplementation and oxygen administration are usually necessary. Haemodialysis is necessary in the anuric patient or in patients with severe</p><p>metabolic acidosis or azotemia, and necessitates more frequent Fomepizole Injection dosing as in 4.2 above.</p><p>&nbsp;</p><p>There is a potential risk of muscle damage resulting from creatine kinase elevation with use of fomepizole. Medical professionals are warned of the potential risk of hypoglycaemia and/or seizures with use of fomepizole.</p><p>&nbsp;</p><p>Treatment success may be assessed by measurements of blood gases, pH, electrolytes, blood urea, creatinine, and urinalysis, in addition to laboratory tests as indicated by individual patient conditions. Plasma and urine concentrations of ethylene glycol and presence of urinary oxalate crystals can be monitored throughout treatment to assess the status of ethylene glycol and metabolite clearance. Severe acidosis or electrolyte imbalance may necessitate appropriate cardiovascular monitoring. Electroencephalography may be indicated in the comatose patient.</p><p><strong>&nbsp;</strong></p><p><strong>Do not use polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) when diluting or administering Fomepizole Injection, 1.5 g/1.5 mL (1 g/mL). Fomepizole can interact with polycarbonate, compromising the integrity of the syringe and/or needle component containing polycarbonate.</strong></p><p>&nbsp;</p><p>Minor allergic reactions (mild rash, eosinophilia) have been reported in a few patients receiving fomepizole (see <strong>ADVERSE REACTIONS</strong>). Therefore, patients should be monitored for signs of allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral doses of fomepizole (10 to 20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses. Similarly, ethanol decreased the rate of elimination of fomepizole (by approximately 50%) by the same mechanism.</p><p>&nbsp;</p><p>Reciprocal interactions may occur with concomitant use of fomepizole and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied.</p><p>&nbsp;</p><p>Fomepizole has been shown to induce the expression of CYP2E1 and to inhibit its activity. These effects were enhanced in rats that had been exposed to ethanol. Fomepizole may also inhibit other CYP enzymes and therefore may alter the exposure to other drugs that are metabolised by CYP enzymes.</p><p>&nbsp;</p><p>Interactions with disulfiram and medications for psychiatric disorders (anti-depressants, anxiolytics and antipsychotics) have not been established.</p><p>&nbsp;</p><p><strong>Laboratory Tests :</strong></p><p>In addition to specific antidote treatment with fomepizole, patients intoxicated with ethylene glycol or methanol must be managed for metabolic acidosis, acute renal failure (ethylene glycol), adult respiratory distress syndrome, visual disturbances (methanol), and hypocalcemia. Fluid therapy and sodium bicarbonate administration are potential supportive therapies. In addition, potassium and calcium supplementation and oxygen administration are usually necessary. Hemodialysis is necessary in the anuric patient, or in patients with severe metabolic acidosis or azotemia (see <strong>DOSAGE AND</strong></p><p><strong>ADMINISTRATION</strong>). Treatment success should be assessed by frequent measurements of blood gases, pH, electrolytes, BUN, creatinine, and urinalysis, in addition to other laboratory tests as indicated by individual patient conditions. At frequent intervals throughout the treatment, patients poisoned with ethylene glycol should be monitored for ethylene glycol concentrations in serum and urine, and the</p><p>presence of urinary oxalate crystals. Similarly, serum methanol concentrations should be monitored in patients poisoned with methanol. Electrocardiography should be performed because acidosis and electrolyte imbalances can affect the cardiovascular system. In the comatose patient, electroencephalography may also be required. In addition, hepatic enzymes and white blood cell counts should be monitored during treatment, as transient increases in serum transaminase concentrations and eosinophilia have been noted with repeated fomepizole dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Pregnancy Category C: Animal reproduction studies have not been conducted with fomepizole. It is also not known whether fomepizole can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Fomepizole should be given to pregnant women only if clearly needed.</p><p>&nbsp;</p><p><strong><u>Lactation (Nursing Mothers) :</u></strong></p><p>It is not known whether fomepizole is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when fomepizole is administered to a nursing woman.</p><p>&nbsp;</p><p><strong><u>Fertility</u></strong></p><p>No fertility studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The possible risks of dizziness and vertigo related to the treatment should be pointed out.</p><p>It is not advisable to drive or use machines during the first few days after treatment is discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>&nbsp;</u></p><p>A total of 141 patients were exposed to fomepizole during the clinical trial period, including both patients (n=78) and healthy volunteers (n=63).</p><p>&nbsp;</p><p><u>Adverse events that occurred in at least 2% of patients treated with fomepizole for either methanol or</u> <u>ethylene glycol poisoning or at least 2% of healthy volunteers in clinical trials</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:622px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Body system/Adverse event</strong></p></td><td style="vertical-align:top"><p><strong>Number (%) of patients with adverse events (n=78)</strong></p></td><td style="vertical-align:top"><p><strong>Number (%) of healthy</strong></p><p><strong>volunteers with adverse events (n = 63)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Body as a whole</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top"><p>14.1%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>11.5%</p></td><td style="vertical-align:top"><p>20.6%</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain/Tenderness</p></td><td style="vertical-align:top"><p>6.4%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Bleeding at venipuncture site</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Backache/Lumbalgia</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Feeling drunk</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>3.2%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Urogenital system</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>14.1%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Worsening/increasing acute renal</p></td><td style="vertical-align:top"><p>3.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>failure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anuria</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system</strong></p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>7.7%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Seizure</p></td><td style="vertical-align:top"><p>3.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>3.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Increased drowsiness</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>11.1%</p></td></tr><tr><td style="vertical-align:top"><p>Toxic encephalopathy</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>1.3%</p></td><td style="vertical-align:top"><p>14.3%</p></td></tr><tr><td style="vertical-align:top"><p>Lightheadedness</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>6.3%</p></td></tr><tr><td style="vertical-align:top"><p>Burning/tingling in vein</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>3.2%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal system</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>7.7%</p></td><td style="vertical-align:top"><p>1.6%</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>22.2%</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal bleeding</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Haematemesis</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea/Loose stool</p></td><td style="vertical-align:top"><p>1.3%</p></td><td style="vertical-align:top"><p>4.8%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiovascular system</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>5.1%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia/sinus bradycardia</p></td><td style="vertical-align:top"><p>3.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Collapse</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Facial flush</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>3.2%</p></td></tr><tr><td style="vertical-align:top"><p>Phlebosclerosis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>3.2%</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolic and nutritional disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and appendages</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>3.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory system</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Sinusitis</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Pulmonary oedema</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Rhinorrhea/Rhinitis</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>6.4%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Lymphangitis</p></td><td style="vertical-align:top"><p>3.8%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>Disseminated intravascular</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>coagulation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eosinophilia/hypereosinophilia</p></td><td style="vertical-align:top"><p>2.6%</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Special Senses</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bad/metallic taste</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>12.7%</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal smell</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4.8%</p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Table of Adverse Reactions &ndash; Possibly, Probably, Definitely or Unknown Relationship to Fomepizole</u> <u>from clinical trials and literature.</u></p><p><u>&nbsp;</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:625px"><tbody><tr><td><p><strong>Body system</strong></p></td><td><p><strong>Very common</strong></p><p><strong>&ge; 10%</strong></p></td><td><p><strong>Common</strong></p><p><strong>&ge;1% and ˂ 10%</strong></p></td><td><p><strong>Uncommon</strong></p><p><strong>&ge;0.1% and ˂1%</strong></p></td></tr><tr><td><p><strong>Body as a whole</strong></p></td><td><p>Headache</p></td><td><p>Abdominal pain Bleeding at venipuncture site Fever</p></td><td><p>Multiorgan system failure* Pain during 4MP injection Inflammation of left arm Lumbalgia/ Backache</p><p>Hangover</p></td></tr><tr><td><p><strong>Urogenital system</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>Anuria*</p></td></tr><tr><td><p><strong>Nervous system</strong></p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>-</p></td><td><p>Dizziness Increased drowsiness</p><p>Lightheadedness Seizure* Agitation* Feeling drunk Facial flush Vertigo</p><p>Burning/tingling in vein</p></td><td><p>Nystagmus Anxiety*</p><p>Felt strange</p><p>Decreased environmental awareness</p></td></tr><tr><td><p><strong>Gastrointestinal system</strong></p></td><td><p>Nausea</p></td><td><p>Vomiting Diarrhoea</p></td><td><p>Dyspepsia*</p><p>Heartburn Decreased appetite</p></td></tr><tr><td><p><strong>Cardiovascular system</strong></p></td><td><p>-</p></td><td><p>Bradycardia/sinus bradycardia Phlebosclerosis</p><p>Hypertension*</p></td><td><p>Tachycardia Hypotension* Phlebitis</p><p>Collapse</p></td></tr><tr><td><p><strong>Skin and appendages</strong></p></td><td><p>-</p></td><td><p>Application site reaction Rash</p></td><td><p>-</p></td></tr><tr><td><p><strong>Respiratory system</strong></p></td><td><p>-</p></td><td><p>-</p></td><td><p>Hiccups Pharyngitis</p></td></tr><tr><td><p><strong>Blood and lymphatic system</strong></p></td><td><p>-</p></td><td><p>Eosinophilia/ hypereosinophilia Lymphangitis*</p></td><td><p>Disseminated intravascular coagulation*</p><p>Anaemia</p></td></tr><tr><td><p><strong>Special senses</strong></p></td><td><p>-</p></td><td><p>Bad taste/metallic taste Abnormal smell Speech/visual disturbances</p><p>Transient blurred vision</p></td><td><p>Roar in ear</p></td></tr></tbody></table><p><em>*Unknown relationship to fomepizole</em></p><p>&nbsp;</p><p><strong>To report any side effect(s):<br />Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&bull; The National Pharmacovigilance Centre (NPC)<br />&bull; &bull;SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong>Other GCC states /other countries</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>-Please contact the relevant competent authority</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nausea, dizziness, and vertigo were noted in healthy volunteers receiving 50 and 100 mg/kg doses of fomepizole (at plasma concentrations of 290 to 520 &mu;mol/L, 23.8 to 42.6 mg/L). These doses are 3 to 6 times the recommended dose. This dose-dependent CNS effect was short-lived in most subjects and lasted up to 30 hours in one subject. Fomepizole is dialyzable, and hemodialysis may be useful in treating cases of overdosage.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antidote, ATC code: V03AB34</p><p>&nbsp;</p><p><u>Pharmacodynamics</u></p><p>Fomepizole is a competitive inhibitor of alcohol dehydrogenase (ADH). ADH catalyses the first stage of the metabolism of ethylene glycol in the liver. Fomepizole treatment blocks the formation of the toxic metabolites of ethylene glycol and prolongs its plasma half-life. Ethylene glycol is thus eliminated unchanged in urine and induces osmotic polyuria.</p><p>The spontaneous 4-hour plasma half-life of ethylene glycol is extended to 10-16 hours with fomepizole.</p><p>The efficacy of fomepizole in the treatment of ethylene glycol poisoning has been shown in dogs and monkeys, with loading doses of 20 and 50 mg/kg, respectively.</p><p>In healthy volunteers, pharmacological effects of fomepizole have been shown indirectly, by the demonstration of a metabolic interaction with ethanol, which is also metabolised by ADH. Doses of fomepizole ranging from 7 to 20 mg/kg are efficient both orally or intravenously.</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>Fomepizole is a competitive inhibitor of alcohol dehydrogenase. Alcohol dehydrogenase catalyzes the oxidation of ethanol to acetaldehyde. Alcohol dehydrogenase also catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.</p><p>&nbsp;</p><p>Ethylene glycol, the main component of most antifreezes and coolants, is metabolized to glycoaldehyde, which undergoes subsequent sequential oxidations to yield glycolate, glyoxylate, and oxalate. Glycolate and oxalate are the metabolic byproducts primarily responsible for the metabolic acidosis and renal damage seen in ethylene glycol toxicosis. The lethal dose of ethylene glycol in humans is approximately 1.4mL/kg.</p><p>&nbsp;</p><p>Methanol, the main component of windshield wiper fluid, is slowly metabolized via alcohol dehydrogenase to formaldehyde with subsequent oxidation via formaldehyde dehydrogenase to yield formic acid. Formic acid is primarily responsible for the metabolic acidosis and visual disturbances (e.g., decreased visual acuity and potential blindness) associated with methanol poisoning. A lethal dose of methanol in humans is approximately 1 to 2mL/kg.</p><p>&nbsp;</p><p>Fomepizole has been shown in vitro to block alcohol dehydrogenase enzyme activity in dog, monkey, and human liver. The concentration of fomepizole at which alcohol dehydrogenase is inhibited by 50% in vitro is approximately 0.1&mu;mol/L. In a study of dogs given a lethal dose of ethylene glycol, three animals each were administered fomepizole, ethanol, or left untreated (control group). The three animals in the untreated group became progressively obtunded, moribund, and died. At necropsy, all three dogs had severe renal tubular damage. Fomepizole or ethanol, given 3 hours after ethylene glycol ingestion, attenuated the metabolic acidosis and prevented the renal tubular damage associated with ethylene glycol intoxication.</p><p>Several studies have demonstrated that fomepizole plasma concentrations of approximately 10 &mu;mol/L (0.82 mg/L) in monkeys are sufficient to inhibit methanol metabolism to formate, which is also mediated by alcohol dehydrogenase. Based on these results, concentrations of fomepizole in humans in the range of 100 to 300 &mu;mol/L (8.6 to 24.6 mg/L) have been targeted to assure adequate plasma concentrations for the effective inhibition of alcohol dehydrogenase.</p><p>In healthy volunteers, oral doses of fomepizole (10 to 20 mg/kg) significantly reduced the rate of elimination of moderate doses of ethanol, which is also metabolized through the action of alcohol dehydrogenase.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The plasma half-life of fomepizole varies with dose, even in patients with normal renal function, and has not been calculated.</p><p><strong>&nbsp;</strong></p><p><strong>Distribution :</strong></p><p>After intravenous infusion, fomepizole rapidly distributes to total body water. The volume of distribution is between 0.6 L/kg and 1.02L/kg.</p><p><strong>&nbsp;</strong></p><p><strong>Metabolism :</strong></p><p>In healthy volunteers, only 1 to 3.5% of the administered dose of fomepizole (7 to 20 mg/kg oral and IV) was excreted unchanged in the urine, indicating that metabolism is the major route of elimination. In humans, the primary metabolite of fomepizole is 4- carboxypyrazole (approximately 80 to 85% of administered dose), which is excreted in the urine. Other metabolites of fomepizole observed in the urine are 4- hydroxymethylpyrazole and the N-glucuronide conjugates of 4-carboxypyrazole and 4</p><p>hydroxymethylpyrazole.</p><p><strong>&nbsp;</strong></p><p><strong>Excretion :</strong></p><p>The elimination of fomepizole is best characterized by Michaelis-Menten kinetics after acute doses, with saturable elimination occurring at therapeutic blood concentrations [100 to 300 &mu;mol/L, 8.2 to 24.6mg/L].</p><p>&nbsp;</p><p>With multiple doses, fomepizole rapidly induces its own metabolism via the cytochrome P450 mixed-function oxidase system, which produces a significant increase in the elimination rate after about 30 to 40 hours. After enzyme induction, elimination follows first-order kinetics.</p><p>&nbsp;</p><p><u>Specific Populations</u></p><p><u>&nbsp;</u></p><p><em>Geriatric :</em></p><p>Fomepizole Injection has not been studied sufficiently to determine whether the pharmacokinetics differ for a geriatric population.</p><p><em>&nbsp;</em></p><p><em>Pediatric :</em></p><p>Fomepizole has not been studied sufficiently to determine whether the pharmacokinetics differ for a pediatric population.</p><p><em>&nbsp;</em></p><p><em>Gender :</em></p><p>Fomepizole has not been studied sufficiently to determine whether the pharmacokinetics differ between the genders.</p><p><em>&nbsp;</em></p><p><em>Renal Insufficiency :</em></p><p>The metabolites of fomepizole are excreted renally. Definitive pharmacokinetic studies have not been done to assess pharmacokinetics in patients with renal impairment.</p><p><em>&nbsp;</em></p><p><em>Hepatic Insufficiency :</em></p><p>Fomepizole is metabolized through the liver, but no definitive pharmacokinetic studies have been done in subjects with hepatic disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenesis, Mutagenesis, Impairment of Fertility</u></p><p>There have been no long-term studies performed in animals to evaluate carcinogenic potential. There was a positive Ames test result in the Escherichia coli tester strain WP2uvrA and the Salmonella typhimurium tester strain TA102 in the absence of metabolic activation. There was no evidence of a clastogenic effect in the in vivo mouse micronucleus assay. In rats, fomepizole (110 mg/kg) administered orally for 40 to 42 days resulted in decreased testicular mass (approximately 8% reduction). This dose is approximately 0.6 times the human maximum daily exposure based on surface area (mg/m<sup>2</sup>). This reduction was similar for rats treated with either ethanol or fomepizole alone. When</p><p>fomepizole was given in combination with ethanol, the decrease in testicular mass was significantly greater (approximately 30% reduction) compared to those rats treated exclusively with fomepizole or ethanol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
36 Months.

After dilution
Fomepizole diluted in 0.9% sodium chloride injection or dextrose 5% injection remains stable and sterile for at least 24 hours when stored refrigerated or at room temperature. 

Fomepizole does not contain preservatives. Therefore, maintain sterile conditions, and after dilution do not use beyond 24 hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2 mL clear USP type I glass vial sealed with 13 mm dark grey bromobutyl rubber stopper and sealed with 13 mm blue color flip-off aluminium seal.</p><p>&nbsp;</p><p>Fomepizole Injection is available as a sterile, preservative-free solution for intravenous use, in vials containing 1.5 mL (1 g/mL) of fomepizole.</p><p>&nbsp;</p><p>Fomepizole injection is supplied in cartons of one single use vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only. Any unused product must be discarded.</p><p>Fomepizole injection concentrate for solution for infusion, is to be diluted before use.</p><p>The concentrate should be diluted with 0.9 % sodium chloride solution or 5 % glucose solution for intravenous use.</p><p>&nbsp;</p><p>Solutions showing haziness, particulate matter, precipitate, discoloration, or leakage should not be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Navinta LLC,
1499 Lower Ferry Road,
Ewing, NJ-08618-1414, USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of revision of the text September 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>